menu
    • menu
    [{"orgOrder":0,"company":"Aptorum","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"SACT-1","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Covar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"SACT-COV19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Aptorum Group","highestDevelopmentStatusID":"1","companyTruncated":"Aptorum \/ Aptorum Group"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptorum","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ALS-4","moa":"Staphyloxathin synthesis","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Aptorum","highestDevelopmentStatusID":"4","companyTruncated":"Aptorum \/ Aptorum"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SACT-1","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SACT-1","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dioscorea Polystachya","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Aenco Technologies Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Rilpivirine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Aenco Technologies Limited","highestDevelopmentStatusID":"6","companyTruncated":"Aptorum \/ Aenco Technologies Limited"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NativusWell","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ALS-4","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rilpivirine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptorum \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aptorum

    Menu

    Aptorum

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilpivirine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblast...

                            Details : SACT-1 (rilpivirine hydrochloride) is an orally administered repurposed small molecule drug for the treatment of neuroblastoma. SACT-1 enhance tumor cell death and suppress MYCN expression.

                            Brand Name : SACT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2023

                            Lead Product(s) : Rilpivirine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALS-4

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Mol...

                            Details : ALS-4 is a small molecule drug based on an anti-virulence approach targeting staphylococcus aureus including MRSA. It targets antimicrobial resistant properties of the bacteria and is believed to render the bacteria highly susceptible to the host’s imm...

                            Brand Name : ALS-4

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2023

                            Lead Product(s) : ALS-4

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NativusWell

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

                            Details : NativusWell® contains a novel, non-hormonal bioactive ingredient DOI, having anti-ageing and antioxidant effect is designed to support the overall health of women undergoing perimenopause, menopause and postmenopause.

                            Brand Name : NativusWell

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2023

                            Lead Product(s) : NativusWell

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilpivirine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Aenco Technologies Limited

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

                            Details : SACT-1 (rilpivirine) is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated to enhance tumor cell death and suppress MYCN expression.

                            Brand Name : SACT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 16, 2022

                            Lead Product(s) : Rilpivirine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Aenco Technologies Limited

                            Deal Size : $3.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dioscorea Polystachya

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

                            Details : NativusWell (dioscorea polystachya) contains a novel, non-hormonal bioactive ingredient DOI, designed to support health of women undergoing perimenopause, menopause and postmenopause.

                            Brand Name : NativusWell

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2022

                            Lead Product(s) : Dioscorea Polystachya

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SACT-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, Targeting Neuroblastoma

                            Details : SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression.

                            Brand Name : SACT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : SACT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SACT-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neurobl...

                            Details : USFDA has granted Orphan Drug Designation to SACT-1, an orally administered repurposed small molecule drug to target neuroblastoma on the basis of results that demonstrated enhanced tumor cell death and suppress MYCN expression in the preclinical studies...

                            Brand Name : SACT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2022

                            Lead Product(s) : SACT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Yale University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University

                            Details : Under the arrangement, Aptorum will be responsible for assessing Yale’s originally developed novel immunomodulators against lupus, arthritis, inflammatory bowel diseases, neurodegenerative diseases or other oncology indications.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 22, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Yale University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALS-4

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4

                            Details : The primary objective of the trial is to evaluate the safety and tolerability of SAD and MAD of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.

                            Brand Name : ALS-4

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2021

                            Lead Product(s) : ALS-4

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aptorum

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SACT-1

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aptorum Group Announces Closing of $9.0 Million Public Offering

                            Details : Aptorum Group intends to use the net proceeds to conduct further analyses of SACT-1 and ALS-4, currently on track for IND submission to commence Phase 1b/2a clinical trials and undergoing final stages of IND enabling studies for Phase 1 human clinical tr...

                            Brand Name : SACT-1

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 02, 2020

                            Lead Product(s) : SACT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth